Lymphatic tracer for SLNB





## — Magtrace® makes a difference —

Due to limited availability of radioisotopes, not all patients can access the 'gold standard of care'. Magtrace® removes that barrier, giving more patients access to the treatment they deserve.











## Injection

$\bigcirc$	Long injection window	$\bigcirc$	Optimised patient pathway
$\odot$	Inject on the table	$\odot$	Full scheduling control
$\bigcirc$	Improved patient comfort	$\odot$	No reported anaphylaxis
	Маррі	ing	
$\bigcirc$	Non-radioactive	<b>⊘</b>	Ready in 20 minutes
$\odot$	99.3% detection rate*	$\bigcirc$	Nodes stay marked for weeks
	Surge	ery	
$\bigcirc$	Non-inferior to the 'gold standard'	<b>⊘</b>	Visual node confirmation
$\bigcirc$	Simple to detect	<b>⊘</b>	10% rule applies
$\bigcirc$	Sentimag® probe offers	$\bigcirc$	No radioactive regulation

\*Clinical data available on file at Endomag

## — Magtrace® lymphatic tracer tech specs —

Magtrace® has been designed to make axillary staging simple and accurate - with both physicians and patients in mind.

Detection properties:  Magnetic signal count Visual node discolouration  Injection scheduling:  Flexible injection from minutes to days before surgery  Injection sites:  Subareolar, peritumoral, interstitial  Adverse events:  No reported serious adverse events in 65,000+ cases  Mammo, U/S, CESM/CEDM: Not detectable on images MRI: MRI Conditional (1.5T and 3.0T)  35+ clinical trials + 4 meta-analyses  Data:  50+ hospitals in 13 countries				
Core — Iron oxide Coating — Sugar (carboxydextran) Liquid — Water and salt Non-radioactive  Particle size:  60nm. Optimal for rapid migration and filtration by the sentinel nodes  Detection properties:  Magnetic signal count Visual node discolouration  Injection scheduling: Flexible injection from minutes to days before surgery  Injection sites:  Subareolar, peritumoral, interstitial  Adverse events:  No reported serious adverse events in 65,000+ cases  Mammo, U/S, CESM/CEDM: Not detectable on images MRI: MRI Conditional (1.5T and 3.0T)  35+ clinical trials + 4 meta-analyses  Data:  5,000+ patients 50+ hospitals in 13 countries  Non-inferior across multiple studies. SentiMAGIC studdemonstrated 99.3% vs. 98.6% for Tc <sup>99</sup> + blue dye*	Approved by:	FDA <sup>†</sup> , CE, Health Canada, TGA, MDCO		
Coating — Sugar (carboxydextran) Liquid — Water and salt Non-radioactive  Particle size:  60nm. Optimal for rapid migration and filtration by the sentinel nodes  Detection properties:  Magnetic signal count Visual node discolouration  Flexible injection from minutes to days before surgery  Injection sites:  Subareolar, peritumoral, interstitial  Adverse events:  No reported serious adverse events in 65,000+ cases  Mammo, U/S, CESM/CEDM: Not detectable on images  MRI: MRI Conditional (1.5T and 3.0T)  35+ clinical trials + 4 meta-analyses  Data:  5,000+ patients 50+ hospitals in 13 countries  Non-inferior across multiple studies. SentiMAGIC studies demonstrated 99.3% vs. 98.6% for Tc <sup>99</sup> + blue dye*	Patients treated:	65,000+ globally		
Detection properties:    Magnetic signal count	Material:	Coating — Sugar (carboxydextran) Liquid — Water and salt		
Injection scheduling:  Flexible injection from minutes to days before surgery  Injection sites:  Subareolar, peritumoral, interstitial  Adverse events:  No reported serious adverse events in 65,000+ cases  Mammo, U/S, CESM/CEDM: Not detectable on images  MRI: MRI Conditional (1.5T and 3.0T)  35+ clinical trials + 4 meta-analyses  Data:  5,000+ patients  50+ hospitals in 13 countries  Non-inferior across multiple studies. SentiMAGIC studiemonstrated 99.3% vs. 98.6% for Tc <sup>99</sup> + blue dye*	Particle size:	60nm. Optimal for rapid migration and filtration by the sentinel nodes		
Injection scheduling:  before surgery  Injection sites:  Subareolar, peritumoral, interstitial  Adverse events:  No reported serious adverse events in 65,000+ cases  Mammo, U/S, CESM/CEDM: Not detectable on images  MRI: MRI Conditional (1.5T and 3.0T)  35+ clinical trials + 4 meta-analyses  Data:  5,000+ patients  50+ hospitals in 13 countries  Non-inferior across multiple studies. SentiMAGIC studies demonstrated 99.3% vs. 98.6% for Tc <sup>99</sup> + blue dye*	Detection properties:			
Adverse events:  No reported serious adverse events in 65,000+ cases  Mammo, U/S, CESM/CEDM: Not detectable on images  MRI: MRI Conditional (1.5T and 3.0T)  35+ clinical trials + 4 meta-analyses  Data:  5,000+ patients  50+ hospitals in 13 countries  Non-inferior across multiple studies. SentiMAGIC studies demonstrated 99.3% vs. 98.6% for Tc <sup>99</sup> + blue dye*	Injection scheduling:			
Imaging:  Mammo, U/S, CESM/CEDM: Not detectable on images  MRI: MRI Conditional (1.5T and 3.0T)  35+ clinical trials + 4 meta-analyses  Data:  5,000+ patients  50+ hospitals in 13 countries  Non-inferior across multiple studies. SentiMAGIC studies demonstrated 99.3% vs. 98.6% for Tc <sup>99</sup> + blue dye*	Injection sites:	Subareolar, peritumoral, interstitial		
Imaging:  MRI: MRI Conditional (1.5T and 3.0T)  35+ clinical trials + 4 meta-analyses  5,000+ patients 50+ hospitals in 13 countries  Non-inferior across multiple studies. SentiMAGIC studies demonstrated 99.3% vs. 98.6% for Tc <sup>99</sup> + blue dye*	Adverse events:	No reported serious adverse events in 65,000+ cases		
Data: 5,000+ patients  50+ hospitals in 13 countries  Non-inferior across multiple studies. SentiMAGIC studies demonstrated 99.3% vs. 98.6% for Tc <sup>99</sup> + blue dye*	Imaging:	Mammo, U/S, CESM/CEDM: Not detectable on images MRI: MRI Conditional (1.5T and 3.0T)		
Detection rate:  demonstrated 99.3% vs. 98.6% for Tc <sup>99</sup> + blue dye*	Data:	5,000+ patients		
Avg. nodes per patient 2.4 vs. 2,4 for Technetium + blue dye*	Detection rate:	Non-inferior across multiple studies. SentiMAGIC study demonstrated 99.3% vs. 98.6% for Tc <sup>99</sup> + blue dye*		
	Avg. nodes per patient	2.4 vs. 2,4 for Technetium + blue dye*		

<sup>\*</sup>Clinical data available on file at Endomag

 $<sup>{}^{\</sup>dagger}\text{FDA}$  Approved for sentinel lymph node biopsy in patients having a mastectomy



Improving breast cancer treatment for everyone.

Contact us at

endomag.com/get-in-touch

MAG-TRACE-SPEC-202101-101